US › Healthcare

Climb Bio Inc (CLYM)

US · Healthcare · Biotechnology

$12.56+6.35%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-13.7M

Profit YoY

+34.0%

EPS

$-0.20

EPS estimate

$-0.30

EPS came in at -0.20 against a street estimate of -0.30 — a beat of 33.3%.

Key statistics

Market cap

$681.4M

Forward P/E

0.0

P/B

4.59

Book value

$3.10

EPS (TTM)

$-0.77

52-week high

$14.41

52-week low

$1.54

50-day MA

$12.14

200-day MA

$7.07

Beta

0.07

Analyst view

Analysts rate Climb Bio Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $20.85.

Shareholding

Insiders

0.37%

Institutions

64.67%

Largest institutional holders

Fund	Stake
RA Capital Management, LLC	19.74%
MPM Oncology Impact Management LP	4.53%
T. Rowe Price Associates, Inc.	3.35%
BRAIDWELL LP	2.67%
Great Point Partners LLC	2.33%
Millennium Management LLC	2.23%
Vanguard Capital Management, LLC	2.06%
Kynam Capital Management, LP	1.75%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Climb Bio Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.